According to the Zhitong Finance App, Danno Pharmaceutical-B (06872.HK) announced that the company has completed the first multi-center phase IIb clinical trial of rifuquinone (TNP-2092), a new drug candidate under development to treat artificial joint infections (PJI) through intra-articular injection. The trial aims to further evaluate the efficacy, safety, and pharmacokinetic characteristics of rifaquinone (TNP-2092) in treating PJI without debridement or revision surgery, marking a critical stage in the clinical development of this potentially disruptive new drug product.

Zhitongcaijing · 2d ago
According to the Zhitong Finance App, Danno Pharmaceutical-B (06872.HK) announced that the company has completed the first multi-center phase IIb clinical trial of rifuquinone (TNP-2092), a new drug candidate under development to treat artificial joint infections (PJI) through intra-articular injection. The trial aims to further evaluate the efficacy, safety, and pharmacokinetic characteristics of rifaquinone (TNP-2092) in treating PJI without debridement or revision surgery, and marks a critical stage in the clinical development of this potentially disruptive new drug product.